Prognostic Value of EndoPredict Test in Patients with Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Primary Breast Cancer Screened for the Randomized, Double-Blind, Phase III UNIRAD TrialF. Penault-Llorca,F. Dalenc,S. Chabaud,P. Cottu,D. Allouache, D. Cameron,J. Grenier,L. Venat Bouvet,A. Jegannathen,M. Campone,M. Debled,A. -C. Hardy-Bessard,S. Giacchetti,P. Barthelemy,L. Kaluzinski,A. Mailliez,M. -A. Mouret-Reynier,E. Legouffe,A. Cayre, M. Martinez, C. Delbaldo, D. Mollon-Grange, E. J. Macaskill, M. Sephton, L. Stefani, B. Belgadi, M. Winter,H. Orfeuvre,M. Lacroix-Triki,H. Bonnefoi, J. Bliss, J. -l. Canon,J. Lemonnier, F. Andre, T. BachelotESMO open（2024）引用 0|浏览14暂无评分关键词breast cancer,EndoPredict,risk stratification,endocrine therapy,prognostic biomarkerAI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
